A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
This study is testing a new experimental drug called MDNA11, both by itself and combined with an immunotherapy drug called pembrolizumab, to see how well they help the immune system fight advanced solid tumors. Researchers want to find the safest and most effective dose to help patients with various types of hard-to-treat cancers.
Adults aged 18 and older with confirmed advanced or spread-out solid tumors may be able to join. Participants need to be generally active, have well-functioning vital organs like the liver and kidneys, and be willing to follow all study rules.
Participants will receive the study treatment, which involves the experimental drug MDNA11 alone or alongside a standard immunotherapy drug. The medical team will closely monitor your health, check for side effects, and see how your body responds to the treatment.
This study is currently recruiting participants at multiple locations in California, United States. Your care team will guide you on visit schedules and specific locations.
- 1Tests a new immune-boosting drug called MDNA11.
- 2Open to adults with various types of advanced solid tumors.
- 3Currently recruiting patients at study sites in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.